Respiratory inhaler is a device that holds medicine and can be taken by breathing, medicine goes straight into the airways when it is inhaled. It has an advantage over oral route of medicine such as tablets, capsules as smaller dose can be given through inhalers which reduces side effect of medicine. Furthermore, inhalers are safe and effective and provide excellent control. Moreover, it provides good delivery of drug and hence it is considered as best treatment in management of bronchial asthma. Respiratory inhaler is most commonly used to treat pulmonary disease (COPD).

Increase in air pollution affecting respiratory health globally is a major factors contributing to growth of the global respiratory inhaler market. In addition, increase in prevalence of asthma, chronic obstructive respiratory disease and other respiratory diseases contributing to growth of the global respiratory inhaler market. Moreover, rising awareness about respiratory disease globally, coupled with several governments and non-profit organizations providing education and support services, is anticipated to further drive growth of the global respiratory inhaler market over the forecast period.

Patent expiration of major brands and increasing number of generic approvals are major factor restraining growth of the global respiratory inhaler market

However, technological advancements and innovations focusing on development of effective drug delivery device which can reduce adverse drug effect is expected to create new opportunities for major players in the global respiratory inhaler market over the forecast period.

The global respiratory inhaler market report has been segmented on the basis of product type, application, technology, and region. On the basis of region, the global respiratory inhaler market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Do Inquiry About Report Here:

North America market dominates the global respiratory inhaler market in terms of revenue contribution as compared to that of markets in other regions. Europe accounts for second-largest revenue share contribution to the global respiratory inhaler market, followed by markets in Latin America, Asia Pacific, and Middle East & Africa respectively. The market in Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years, owing to increasing prevalence of respiratory diseases in the regions.

Some prominent players in the global respiratory inhalers market are AstraZeneca Plc., Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline Plc., Koninklijke Philips N.V., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Omron Healthcare Europe B.V., PARI Medical Holding, and H&T PRESSPART